Last reviewed · How we verify

Hackensack Meridian Health — Portfolio Competitive Intelligence Brief

Hackensack Meridian Health pipeline: 3 marketed, 0 filed, 1 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 1 Phase 3 6 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Ceftriaxone treatment Ceftriaxone treatment marketed
18F-rhPSMA-7.3 18F-rhPSMA-7.3 marketed PET imaging agent / radiopharmaceutical PSMA (prostate-specific membrane antigen) Oncology
Ketamine Injectable Product Ketamine Injectable Product marketed NMDA receptor antagonist NMDA receptor Anesthesia, Pain Management, Psychiatry
Convalescent Plasma Convalescent Plasma phase 3 Immunoglobulin/Passive immunotherapy Immunology/Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ajou University School of Medicine · 1 shared drug class
  2. Alameda Health System · 1 shared drug class
  3. American University of Beirut Medical Center · 1 shared drug class
  4. Asker & Baerum Hospital · 1 shared drug class
  5. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  6. AstraZeneca · 1 shared drug class
  7. Auris Medical AG · 1 shared drug class
  8. Acacia Pharma Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hackensack Meridian Health:

Cite this brief

Drug Landscape (2026). Hackensack Meridian Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hackensack-meridian-health. Accessed 2026-05-16.

Related